Immunotherapy is increasingly used in earlier cancer stages before or after surgery across seven tumor areas. Research shows neoadjuvant and adjuvant immunotherapy can reduce recurrence risk and improve immune recognition of tumor cells. However, challenges remain including side effects, costs, and determining which patients benefit most from earlier treatment.
Immunotherapy is increasingly being used before and after surgery across seven cancer types, while the global immunotherapy drugs market experiences significant growth driven by advances in biotechnology and targeted therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06545188 |
Impact of Mortality Salience on Treatment Decisions |
COMPLETED | NA |
| NCT05063292 |
Effect of Prewarming On Skin Temperature Changes |
UNKNOWN | NA |
| NCT04299997 |
Evaluation of the PI-RADS v2.1 Score Using Multiple Readers |
COMPLETED | |
| NCT04088968 |
STRONG for Surgery & Strong for Life - Against All Odds: Intensive Prehabilitation for Risk Reduction in Cancer Surgery |
RECRUITING | NA |
| NCT02836795 |
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors |
COMPLETED | PHASE1 |
| NCT02818530 |
Correlation Between Intraocular Pressure Measurement by Tomometer and Anterior Chamber Depth Measurement by Ultrasound |
TERMINATED | NA |
